NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $3.84 -0.17 (-4.24%) Closing price 04:00 PM EasternExtended Trading$3.85 +0.01 (+0.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$3.82▼$4.0550-Day Range$3.09▼$4.7852-Week Range$2.77▼$7.18Volume19.71 million shsAverage Volume30.20 million shsMarket Capitalization$2.06 billionP/E RatioN/ADividend YieldN/APrice Target$8.06Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms. Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience. Its pipeline has included internally discovered and developed drug candidates, as well as programs advanced through collaborations and strategic partnerships. The company’s approach combines laboratory experimentation with computational tools to support target discovery, compound design, preclinical testing and clinical development. Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as an international biotechnology organization through its research activities, partnerships and collaborations. In 2024, Recursion completed a combination with Exscientia plc, a United Kingdom-based company specializing in artificial intelligence-driven drug design, expanding Recursion’s capabilities in computational chemistry and medicine discovery. Recursion was co-founded by Chris Gibson, who serves as chief executive officer.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreRXRX MarketRank™: 2.41102030055 of 5 starsRecursion Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 576th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $8.06, representing about 109.9% upside from its current price of $3.84.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to remain at ($0.94) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted31.60% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 6.13.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently decreased by 11.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.33 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest49 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 123% compared to the previous 30 days.MarketBeat Follows28 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 115% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $643,576.00 in company stock.Percentage Held by Insiders6.65% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesWhat Could Go Wrong With Recursion Pharmaceuticals Stock?October 10 at 3:46 AM | finance.yahoo.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 50,000 SharesOctober 9, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 13 at 1:00 AM | Stansberry Research (Ad)Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 25,000 Shares of StockOctober 8, 2026 | insidertrades.comStock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)October 7, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% - Here's WhyOctober 5, 2026 | americanbankingnews.comRecursion Pharmaceuticals (NASDAQ:RXRX) and Ionis Pharmaceuticals (NASDAQ:IONS) Head-To-Head ComparisonOctober 5, 2026 | americanbankingnews.comMost and least shorted mid- to mega-cap healthcare stocks at the end of SeptemberOctober 2, 2026 | msn.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $4.09 at the beginning of 2026. Since then, RXRX shares have decreased by 6.1% and is now trading at $3.84. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) issued its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. The business had revenue of $7.67 million for the quarter, compared to analysts' expectations of $10.97 million. Recursion Pharmaceuticals had a negative trailing twelve-month return on equity of 50.41% and a negative net margin of 945.94%. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $412 million in an IPO on Thursday, April 15th 2021. The company issued 24,242,424 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. Who are Recursion Pharmaceuticals' major shareholders? Recursion Pharmaceuticals' top institutional shareholders include Green Alpha Advisors LLC (0.04%), Whalen Wealth Management Inc. (0.01%) and Kieckhefer Group LLC (0.01%). Insiders that own company stock include Blake Borgeson, Najat Khan, Michael Secora, Ben R Taylor, Christopher Gibson, Tina Marriott, Dean Y Li, Tina Marriott Larson, Robert Hershberg, Shafique Virani, Namandje Bumpus and Zavain Dar. View institutional ownership trends. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), SoundHound AI (SOUN), Tesla (TSLA), Micron Technology (MU) and IonQ (IONQ). Company Calendar Last Earnings8/05/2026Today10/13/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 8 days, RXRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees600Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$8.06 High Price Target$11.00 Low Price Target$5.30 Potential Upside/Downside+109.9%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.76 million Net Margins-945.94% Pretax Margin-954.29% Return on Equity-50.41% Return on Assets-38.25% Debt Debt-to-Equity Ratio0.01 Current Ratio5.03 Quick Ratio5.03 Sales & Book Value Annual Sales$74.68 million Price / Sales27.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.14 per share Price / Book1.79Miscellaneous Outstanding Shares535,340,000Free Float499,742,000Market Cap$2.06 billion OptionableOptionable Beta1.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:RXRX) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXRX Stock Alerts